Detection of PIK3CA Mutations in Breast Cancer Bone Metastases

Table 2

Clinical features and pathology of cases with known bone metastasis PIK3CA mutation status.

Case		Bone metastasis			Primary			Time from	Time from
	PIK3CA; status	ER status	PgR status	HER2 status	ER status	PgR status	HER2 status	cancer diagnosis (years)	metastatic cancer diagnosis (years)
2	E545K	pos.	pos.	normal	pos.	pos.	normal	11	11
3	WT	pos.	neg.	normal	pos.	neg.	normal	11	1
4	H1047R	pos.	neg.	normal	pos.	pos.	normal	14	2
11	WT	pos.	pos.	normal	pos.	pos.	normal	23	21
12	H1047R hom.	pos.*	neg.*	amplified*	pos.	neg.	amplified	<1	<1
13	WT	pos.	neg.	normal	pos.	pos.	normal	<1	<1

Estrogen (ER) and progesterone (PgR) statuses are shown as positive (pos.) or negative (neg.). Time from cancer diagnosis and metastatic cancer diagnosis is the time between diagnosis and the biopsy taken for this study. *determined from CT-guided bone biopsy; other metastasis receptor and HER2 data are determined from trephine biopsies.